SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose 5.72% Stake in Creative Medical Technology Holdings

Armistice Capital, LLC and Steven Boyd have jointly disclosed a beneficial ownership of 148,000 shares, representing 5.72% of Creative Medical Technology Holdings, Inc.'s common stock.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons', have filed a Schedule 13G.
• The filing indicates beneficial ownership of 148,000 shares of Common Stock, par value $0.001 per share, in Creative Medical Technology Holdings, Inc.
• This ownership represents 5.72% of the issuer's class of securities.
• The percentage is calculated based on 2,585,897 shares outstanding as of April 15, 2025, as reported in the issuer's Form 10-K filed on April 25, 2025.
• Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
• Both reporting persons share voting and dispositive power over the 148,000 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as a significant institutional investor has disclosed a stake, which can be interpreted as a vote of confidence. However, the document itself is a factual disclosure of ownership and does not contain performance-related information.

Positives

• A significant institutional investor, Armistice Capital, LLC, and its managing member, Steven Boyd, have taken a 5.72% stake in Creative Medical Technology Holdings, Inc., which may signal confidence in the company's prospects.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of beneficial ownership by an institutional investor and does not provide specific industry context or trends related to Creative Medical Technology Holdings, Inc.'s operations beyond the fact of an investment firm taking a significant stake.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an institutional investor may influence investor perception and potentially the stock price, indicating institutional interest in the company.

Key Dates

Keywords

Creative Medical Technology Holdings, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, SEC Filing, Institutional Investor